BioStock Article: Aptahem reports growing buzz around Apta-1

Malmö-based Aptahem recently released detailed plans of their upcoming phase II study with candidate Apta-1, set to prove its multifaceted potential and optimise future market opportunities. Meanwhile, the company has intensified partnership discussions, noting increased interest from major players following BIO-Europe in Milan.

Read the full article at Aptahem’s website.

For further information:

Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
E-mail: [email protected]

About Aptahem

Aptahem AB (APTA) is a clinical stage biotechnology company that develops RNA-based pharmaceuticals for the treatment of acute, life-threatening conditions in which a combination of coagulation, inflammation and tissue damage are involved. The company’s lead candidate, Apta-1, is currently in early clinical phase. Apta-1 has in preclinical studies, by its anti-thrombotic, immunomodulating and tissue repairing characteristics, shown very positive and promising results as treatment for sepsis and critical conditions associated with sepsis. For more information, please visit www.aptahem.com.